Satisfaction with Treatment and Interventionist as measured by the Satisfaction with Therapy and Therapist Scale-Revised (STTS-R)

Participants will complete the 13-item Satisfaction with Therapy and Therapist Scale-Revised specific to the program they received. The first 12 items ask participants to rate their agreement with statements related to intervention satisfaction on a 5-point scale ranging from "strongly disagree" (1) to "strongly agree" (5). The 13th item asks "How much did the intervention help with your symptoms?" with 5 answer choices ranging from "made things a lot better" to "made things a lot worse."

Post-treatment (about 12-14 weeks after baseline)

Acceptability as measured by the Treatment Acceptability Questionnaire

The Treatment Acceptability Questionnaire is a six-item scale assessing participants' views of an intervention as acceptable, ethical, and effective. Items are rated on a 7-point Likert scale (e.g., 1 "very unacceptable" to 7 "very acceptable") and averaged.

Post-treatment (about 12-14 weeks after baseline)

Change in blood pressure (systolic and diastolic)

Both systolic and diastolic blood pressure will be assessed at the baseline and follow-up assessment.

From Baseline to Post-treatment (about 12-14 weeks after baseline)

Change in weight

Participants will be weighed at each assessment.

From Baseline to Post-treatment (about 12-14 weeks after baseline)

Change in total cholesterol

Cholesterol will be assessed through peripheral blood at the baseline and follow-up assessment.

From Baseline to Post-treatment (about 12-14 weeks after baseline)

Change in LDL cholesterol

LDL cholesterol will be assessed through peripheral blood at the baseline and follow-up assessment.

From Baseline to Post-treatment (about 12-14 weeks after baseline)

Change in HDL cholesterol

HDL cholesterol will be assessed through peripheral blood at the baseline and follow-up assessment.

From Baseline to Post-treatment (about 12-14 weeks after baseline)

Change in hemoglobin A1c

Hemoglobin A1c will be assessed through peripheral blood at the baseline and follow-up assessment.

From Baseline to Post-treatment (about 12-14 weeks after baseline)

Change in C-reactive protein

C-reactive protein will be assessed through peripheral blood at the baseline and follow-up assessment.

From Baseline to Post-treatment (about 12-14 weeks after baseline)

Change in high sensitivity troponin

High sensitivity troponin will be assessed through peripheral blood at the baseline and follow-up assessment.

From Baseline to Post-treatment (about 12-14 weeks after baseline)

Change in aerobic capacity and endurance as measured by the 6-Minute Walk Test

The 6-minute walk test is a self-paced, timed test of the total distance in meters that a patient is able to walk over a six-minute period and assesses the ability to exert effort during activity. Higher values indicate higher aerobic capacity and endurance.

From Baseline to Post-treatment (about 12-14 weeks after baseline)

Pain severity and interference as measured by the Brief Pain Inventory

The Brief Pain Inventory will be used to assess pain severity and interference from pain across important life domains (e.g., general activity, work, relations with others). This measures includes a body map on which the patient can mark the location(s) in which they are experiencing pain, as well as 8 questions on a scale of 0 to 10 with higher scores indicating worse pain severity or pain interference.

Baseline, Post-treatment (about 12-14 weeks after baseline)

Emotional distress as measured by PROMIS Depression Short Form

Depressive symptoms will be assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS) Depression Short Form, an 8-item measure assessing symptoms of depression in the last week. Responses are on a 5-point scale from "never" (1) to "always" (5).

Baseline, Post-treatment (about 12-14 weeks after baseline)

Emotional distress as measured by PROMIS Anxiety Short Form

Symptoms of Anxiety will be assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety Short Form, an 8-item measure assessing symptoms of anxiety in the last week. Responses are on a 5-point scale from "never" (1) to "always" (5).

Baseline, Post-treatment (about 12-14 weeks after baseline)

Fatigue as measured by PROMIS Fatigue Scale

Fatigue will be assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Scale, a 6-item self-report measure of fatigue. Participants are asked to think about the last week when responding to each item (e.g., "In the past 7 days, how run-down did you feel, on average?"), providing ratings on a scale from "not at all" (1) to "very much" (5).

Baseline, Post-treatment (about 12-14 weeks after baseline)

Diet as measured by the Dietary Screener Questionnaire

The Dietary Screener Questionnaire is a 25-item measure asking participants to rate on the frequency of eating/drinking certain foods in the last week.

Baseline, Post-treatment (about 12-14 weeks after baseline)

Eating behavior as measured by the Three Factor Eating Questionnaire

Eating behaviors will be assessed using the Three Factor Eating Questionnaire (TFEQ). The 21-item short-form will be used for the present study. The TFEQ measures three domains of eating behavior: 1) cognitive restraint, 2) uncontrolled eating, and 3) emotional eating.

Baseline, Post-treatment (about 12-14 weeks after baseline)

Physical activity as measured by the Stanford Leisure-Time Activity Categorical Item (L-Cat)

The L-Cat is a measure of physical activity. Individuals identify which descriptive category best describes their level of activity during leisure time in the last month. Descriptive categories range from inactive to very active.

Baseline, Post-treatment (about 12-14 weeks after baseline)

Patient self-efficacy for chronic disease coping as measured by Self-Efficacy for Managing Chronic Illness Scale

The 6-item Self-Efficacy for Managing Chronic Illness Scale will be used to assess participants' current confidence in their ability to prevent symptoms (e.g., pain, fatigue, distress) from interfering with life. Responses are on a 10-point scale from "not at all confident" (1) to "totally confident" (10).

Baseline, Post-treatment (about 12-14 weeks after baseline)

Patient self-efficacy for managing chronic conditions as measured by the PROMIS Self-Efficacy for Managing Symptoms Short Form

The 4-item PROMIS Self-Efficacy for Managing Symptoms will be used to assess participants' confidence in their ability to manage symptoms (e.g. during daily activities, in a public place). Items are scored on a 5-point Likert scale, with higher scores indicating greater confidence.

Baseline, Post-treatment (about 12-14 weeks after baseline)

Weight-related self-efficacy as measured by the Weight Efficacy Lifestyle Questionnaire

The Weight Efficacy Lifestyle Questionnaire is an 8-item measure of eating self-efficacy. Participants are asked to provide information about how certain they are that they can resist overeating in difficult situation (e.g., over the weekend, when tired, etc.). Response choices range from 0= "not at all confident" to 10= "very confident."

Baseline, Post-treatment (about 12-14 weeks after baseline)